Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study)-Reference-Cited by-同舟云学术

Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study)

Published:2020-10 Issue:1 Volume:159 Page:256-263
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Robelin Patrick,Tod Michel,Colomban Olivier,Lachuer Joel,Ray-Coquard Isabelle,Rauglaudre Gaëtan De,Joly Florence,Chevalier-Place Annick,Combe Pierre,Lortholary Alain,Hamizi Salima,Raban Nadia,Ferron Gwénaël,Meunier Jérôme,Berton-Rigaud Dominique,Alexandre Jérôme,Kaminsky Marie-Christine,Dubot Coraline,Leary Alexandra,Malaurie Emmanuelle,You Benoit

Funder

ARCAGY GINECO

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference36 articles.

1. Cancer statistics, 2017;Siegel;CA Cancer J. Clin.,2017

2. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG);Rustin;Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc.,2011

3. Two prognostic populations of ovarian cancer patients defined by CA125 modeled kinetic parameter KELIM (AGO-OVAR 7 & 9; ICON 7 AGO/GINECO/ MRC CTU/GCIG trials);You;J. Clin. Oncol.,2017

4. Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy;Azad;Cancer,2008

5. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial;Rustin;Lancet Lond. Engl.,2010

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors;Molecular Oncology;2024-08-11

2. Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine;Frontiers in Pharmacology;2023-03-07

3. Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial;Gynecologic Oncology;2023-03

4. Insight on Non-Coding RNAs from Biofluids in Ovarian Tumors;Cancers;2023-02-28

5. Circulating microRNAs as Reliable Tumor Biomarkers: Opportunities and Challenges Facing Clinical Application;Journal of Pharmacology and Experimental Therapeutics;2022-07-09